NCT00979576 - BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 16, 2009

Primary Completion Date

February 16, 2015

Study Completion Date

February 16, 2015

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

BIBF 1120 M + Pemetrexed

BIBF 1120 medium dose bid+ Pemetrexed 500 mg/m\^2

DRUG

BIBF 1120 H + Pemetrexed

BIBF 1120 high dose bid+ Pemetrexed 500 mg/m\^2

DRUG

BIBF 1120 RD + Pemetrexed

confirmed dose of BIBF 1120 bid + Pemetrexed 500 mg/m\^2

DRUG

BIBF 1120 L + Pemetrexed

BIBF 1120 low dose bid+ Pemetrexed 500 mg/m\^2

DRUG

BIBF 1120 Placebo + Pemetrexed

placebo BIBF 1120 bid + Pemetrexed 500 mg/m\^2

Trial Locations (3)

1199.28.003 Boehringer Ingelheim Investigational Site, Chiba,Kashiwa

1199.28.002 Boehringer Ingelheim Investigational Site, Miyakojima-ku, Osaka

1199.28.001 Boehringer Ingelheim Investigational Site, Osaka-Sayama, Osaka